Compare Stocks: PEPG, DSGN, DBVT, and ACRS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$5.57 -0.1%	$5.79	$1.74 ▼ $6.60	$778.10M	0.79	2.00 million shs	480,694 shs
DBVT DBV Technologies	$12.12 +0.1%	$13.78	$8.85 ▼ $26.18	$762.17M	-0.95	299,566 shs	109,503 shs
DSGN Design Therapeutics	$12.94 +3.1%	$13.85	$5.28 ▼ $17.25	$810.10M	1.66	602,162 shs	103,208 shs
PEPG PepGen	$2.94 +3.3%	$2.68	$1.31 ▼ $7.80	$203.28M	1.97	1.03 million shs	256,264 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	+1.27%	-1.24%	-13.10%	+13.21%	+191.62%
DBVT DBV Technologies	-2.02%	-2.02%	-16.84%	-24.89%	+27.37%
DSGN Design Therapeutics	+2.53%	-7.17%	-16.28%	-8.66%	+107.44%
PEPG PepGen	-0.35%	-4.38%	-9.55%	+56.04%	+51.06%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$5.57 -0.1%	$5.79	$1.74 ▼ $6.60	$778.10M	0.79	2.00 million shs	480,694 shs
DBVT DBV Technologies	$12.12 +0.1%	$13.78	$8.85 ▼ $26.18	$762.17M	-0.95	299,566 shs	109,503 shs
DSGN Design Therapeutics	$12.94 +3.1%	$13.85	$5.28 ▼ $17.25	$810.10M	1.66	602,162 shs	103,208 shs
PEPG PepGen	$2.94 +3.3%	$2.68	$1.31 ▼ $7.80	$203.28M	1.97	1.03 million shs	256,264 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	+1.27%	-1.24%	-13.10%	+13.21%	+191.62%
DBVT DBV Technologies	-2.02%	-2.02%	-16.84%	-24.89%	+27.37%
DSGN Design Therapeutics	+2.53%	-7.17%	-16.28%	-8.66%	+107.44%
PEPG PepGen	-0.35%	-4.38%	-9.55%	+56.04%	+51.06%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$11.33	103.65% Upside
DBVT DBV Technologies	2.57	Moderate Buy	$48.50	300.33% Upside
DSGN Design Therapeutics	2.88	Moderate Buy	$16.50	27.56% Upside
PEPG PepGen	2.71	Moderate Buy	$11.50	291.82% Upside

Current Analyst Ratings Breakdown

Latest PEPG, DSGN, DBVT, and ACRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	DBVT DBV Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/9/2026	PEPG PepGen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/1/2026	ACRS Aclaris Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
9/1/2026	ACRS Aclaris Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
8/28/2026	PEPG PepGen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	DBVT DBV Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	DSGN Design Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/30/2026	DBVT DBV Technologies	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/30/2026	DBVT DBV Technologies	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$47.00 ➝ $55.00
6/29/2026	DBVT DBV Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/24/2026	ACRS Aclaris Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$7.83M	99.37	N/A	N/A	$0.85 per share	6.55
DBVT DBV Technologies	$5.64M	135.07	N/A	N/A	$4.20 per share	2.88
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$3.73 per share	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	$2.14 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$64.92M	-$0.58	N/A	N/A	N/A	-921.50%	-61.65%	-42.41%	11/5/2026 (Estimated)
DBVT DBV Technologies	-$146.95M	-$3.51	N/A	N/A	N/A	-3,506.53%	-119.33%	-84.43%	10/28/2026 (Estimated)
DSGN Design Therapeutics	-$69.79M	-$1.18	N/A	N/A	N/A	N/A	-34.03%	-32.05%	11/4/2026 (Estimated)
PEPG PepGen	-$89.65M	-$1.31	N/A	N/A	N/A	N/A	-51.01%	-43.49%	11/11/2026 (Estimated)

Latest PEPG, DSGN, DBVT, and ACRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	ACRS Aclaris Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	$1.38 million	$1.63 million
8/6/2026	Q2 2026	PEPG PepGen	-$0.2845	-$0.26	+$0.0245	-$0.26	N/A	N/A
8/3/2026	Q2 2026	DSGN Design Therapeutics	-$0.3443	-$0.32	+$0.0243	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	3.46	3.46
DBVT DBV Technologies	N/A	3.72	3.72
DSGN Design Therapeutics	N/A	18.86	18.86
PEPG PepGen	N/A	13.36	13.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
DBVT DBV Technologies	71.74%
DSGN Design Therapeutics	56.64%
PEPG PepGen	58.01%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	4.80%
DBVT DBV Technologies	1.06%
DSGN Design Therapeutics	17.10%
PEPG PepGen	1.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	73	139.82 million	133.11 million	Optionable
DBVT DBV Technologies	161	62.88 million	62.21 million	Optionable
DSGN Design Therapeutics	55	62.58 million	51.88 million	Optionable
PEPG PepGen	57	69.26 million	68.36 million	Not Optionable

PEPG, DSGN, DBVT, and ACRS Headlines

Recent News About These Companies

PepGen, Inc. $PEPG Shares Bought by Squarepoint Ops LLC

September 18, 2026 | marketbeat.com

PepGen Inc. (PEPG) Interactive Stock Chart - Yahoo Finance

September 16, 2026 | finance.yahoo.com

PepGen, Inc. (NASDAQ:PEPG) Given Consensus Recommendation of "Moderate Buy" by Analysts

September 15, 2026 | americanbankingnews.com

PepGen (NASDAQ:PEPG) Earns Buy Rating from HC Wainwright

September 11, 2026 | americanbankingnews.com

PepGen, Inc. (NASDAQ:PEPG) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

September 10, 2026 | marketbeat.com

HC Wainwright Reiterates Buy Rating for PepGen (NASDAQ:PEPG)

September 9, 2026 | marketbeat.com

BlackRock Inc. Buys Shares of 1,304,262 PepGen, Inc. $PEPG

September 6, 2026 | marketbeat.com

ADAR1 Capital Management LLC Acquires New Shares in PepGen, Inc. $PEPG

August 26, 2026 | marketbeat.com

600,000 Shares in PepGen, Inc. $PEPG Purchased by AWM Investment Company Inc.

August 26, 2026 | marketbeat.com

DSMB approves dose escalation in PepGen’s FREEDOM2-DM1 study

August 7, 2026 | msn.com

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

August 6, 2026 | businesswire.com

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

August 6, 2026 | businesswire.com

PepGen Inc. (PEPG) Stock Price, News, Quote & History - Yahoo Finance

July 14, 2026 | finance.yahoo.com

PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

July 8, 2026 | stockhouse.com

PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

May 20, 2026 | zacks.com

10 Best NASDAQ Stocks Under $5 to Buy Right Now

May 18, 2026 | insidermonkey.com

Is PepGen (PEPG) One of the Best NASDAQ Stocks Under $5 to Buy Right Now?

May 18, 2026 | finance.yahoo.com

PepGen (PEPG) Upgraded to Buy: Here's What You Should Know

May 13, 2026 | zacks.com

PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 12, 2026 | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

May 7, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

April 30, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PEPG, DSGN, DBVT, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$5.56 -0.01 (-0.09%)

As of 12:13 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

DBV Technologies NASDAQ:DBVT

$12.12 +0.02 (+0.12%)

As of 12:13 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Design Therapeutics NASDAQ:DSGN

$12.94 +0.39 (+3.07%)

As of 12:13 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

PepGen NASDAQ:PEPG

$2.94 +0.10 (+3.35%)

As of 12:11 PM Eastern

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PEPG, DSGN, DBVT, and ACRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PEPG, DSGN, DBVT, and ACRS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PEPG, DSGN, DBVT, and ACRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PEPG, DSGN, DBVT, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

DBV Technologies NASDAQ:DBVT

Design Therapeutics NASDAQ:DSGN

PepGen NASDAQ:PEPG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PEPG, DSGN, DBVT, and ACRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PEPG, DSGN, DBVT, and ACRS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PEPG, DSGN, DBVT, and ACRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PEPG, DSGN, DBVT, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

DBV Technologies NASDAQ:DBVT

Design Therapeutics NASDAQ:DSGN

PepGen NASDAQ:PEPG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools